Literature DB >> 2167295

Interruption of capsule production in Streptococcus pneumonia serotype 3 by insertion of transposon Tn916.

D A Watson1, D M Musher.   

Abstract

Transposon Tn916 mutagenesis was used to produce mutant strains of Streptococcus pneumoniae serotype 3 that lacked only a polysaccharide capsule. Southern blotting, DNA-DNA hybridization, and immunochemical analyses demonstrated that the presence of a single copy of Tn916 was sufficient to produce unencapsulation. The 50% lethal dose for such mutants was greater than 5 x 10(7) CFU, as opposed to a 50% lethal dose of 1 CFU for wild-type strains. These experiments outline an effective method for targeting genes in S. pneumoniae by transposon interruption and provide molecular evidence to support the longstanding hypothesis that the capsule is the principal virulence factor in this pathogen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167295      PMCID: PMC313622          DOI: 10.1128/iai.58.9.3135-3138.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  Genetic organization of the bacterial conjugative transposon Tn916.

Authors:  E Senghas; J M Jones; M Yamamoto; C Gawron-Burke; D B Clewell
Journal:  J Bacteriol       Date:  1988-01       Impact factor: 3.490

2.  The diagnostic value of sputum culture in acute pneumonia.

Authors:  S B Thorsteinsson; D M Musher; T Fagan
Journal:  JAMA       Date:  1975-08-25       Impact factor: 56.272

3.  Transformation of encapsulated Streptococcus pneumoniae.

Authors:  J Yother; L S McDaniel; D E Briles
Journal:  J Bacteriol       Date:  1986-12       Impact factor: 3.490

4.  Properties of a supercoiled deoxyribonucleic acid-protein relaxation complex and strand specificity of the relaxation event.

Authors:  D B Clewell; D R Helinski
Journal:  Biochemistry       Date:  1970-10-27       Impact factor: 3.162

5.  Transfer of plasmids by conjugation in Streptococcus pneumonias.

Authors:  M D Smith; N B Shoemaker; V Burdett; W R Guild
Journal:  Plasmid       Date:  1980-01       Impact factor: 3.466

6.  Improved method for conjugative transfer by filter mating of Streptococcus pneumoniae.

Authors:  M D Smith; W R Guild
Journal:  J Bacteriol       Date:  1980-10       Impact factor: 3.490

7.  Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation.

Authors:  N B Shoemaker; W R Guild
Journal:  Mol Gen Genet       Date:  1974

8.  Acetylcysteine: a drug with an interesting past and a fascinating future.

Authors:  I Ziment
Journal:  Respiration       Date:  1986       Impact factor: 3.580

9.  Regeneration of insertionally inactivated streptococcal DNA fragments after excision of transposon Tn916 in Escherichia coli: strategy for targeting and cloning of genes from gram-positive bacteria.

Authors:  C Gawron-Burke; D B Clewell
Journal:  J Bacteriol       Date:  1984-07       Impact factor: 3.490

10.  Regulation of expression of the human interferon gamma gene.

Authors:  K J Hardy; B M Peterlin; R E Atchison; J D Stobo
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

View more
  46 in total

1.  Effect of intrastrain variation in the amount of capsular polysaccharide on genetic transformation of Streptococcus pneumoniae: implications for virulence studies of encapsulated strains.

Authors:  J N Weiser; M Kapoor
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  Pneumococcal 6-phosphogluconate-dehydrogenase, a putative adhesin, induces protective immune response in mice.

Authors:  D Daniely; M Portnoi; M Shagan; A Porgador; N Givon-Lavi; E Ling; R Dagan; Y Mizrachi Nebenzahl
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  Transcriptional organization of pneumococcal psrP-secY2A2 and impact of GtfA and GtfB deletion on PsrP-associated virulence properties.

Authors:  Anel Lizcano; Ramya Akula Suresh Babu; Anukul T Shenoy; Alison Maren Saville; Nikhil Kumar; Adonis D'Mello; Cecilia A Hinojosa; Ryan P Gilley; Jesus Segovia; Timothy J Mitchell; Hervé Tettelin; Carlos J Orihuela
Journal:  Microbes Infect       Date:  2017-04-10       Impact factor: 2.700

4.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Identification, cloning, and sequencing of DNA essential for encapsulation of Streptococcus pneumoniae.

Authors:  D A Watson; V Kapur; D M Musher; J W Jacobson; J M Musser
Journal:  Curr Microbiol       Date:  1995-10       Impact factor: 2.188

6.  Molecular basis of virulence.

Authors:  T J Mitchell
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

7.  Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae.

Authors:  D E Briles; M J Crain; B M Gray; C Forman; J Yother
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

8.  Differential activation of the immune system by virulent Streptococcus pneumoniae strains determines recovery or death of the host.

Authors:  Y Mizrachi-Nebenzahl; S Lifshitz; R Teitelbaum; S Novick; A Levi; D Benharroch; E Ling; R Dagan
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

9.  Nucleotide sequence analysis of genes essential for capsular polysaccharide biosynthesis in Streptococcus pneumoniae type 19F.

Authors:  A Guidolin; J K Morona; R Morona; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation.

Authors:  C M Verduin; M Jansze; C Hol; T E Mollnes; J Verhoef; H van Dijk
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.